AcuraStem’s Associate Vice President, Dr. Wen-Hsuan (Wen) Chang, to Present at 3rd Annual ALS Drug Development Summit and Participate in Panel and Roundtable Discussions

AcuraStem Associate Vice President, Discovery and Early Development, Dr. Wen-Hsuan (Wen) Chang, will present on "Employing iPSC-Derived Motor Neurons to Model Diverse Forms of ALS" at the 3rd annual ALS Drug Development Summit on May 22, in Boston. This event promises to be a hub of innovative science and breakthroughs.

Dr. Chang's presentation will take place at 11:00 AM on May 22, 2024, and will cover innovative methods to model familial and sporadic ALS, ensuring confidence in the differentiation stimulus to induce authentic ALS phenotypes, and enhancing the translational value of iPSC-derived models for clinical applications.

Following the presentation, at 12:00 PM, Dr. Chang will participate in a panel discussion titled "Expanding the In Vitro Toolbox to Bring Additional Translational Value to iPSC-Derived Models." This discussion will explore additional avenues to enhance in vitro studies of ALS pathology, evaluate the ability to model neuromuscular junctions using sophisticated systems such as organoids and microfluidics, and debate the feasibility of employing novel in vitro methods for preclinical studies in the industry.

At 2:40 PM, Dr. Chang will take part in a roundtable discussion on "Reinventing the ALS Target Landscape," focusing on looking beyond TDP-43 to investigate other RNA binding protein dysfunctions involved in sporadic ALS. These practical and interactive breakout sessions will allow attendees to crowd-source solutions and share opinions on pre-assigned topics.

The 3rd Annual ALS Drug Development Summit is a significant event in the ALS research community, focusing on the latest advancements in preclinical and clinical R&D. The summit will feature two dedicated tracks of content, showcasing novel approaches to target ALS-related proteins using genome editing technologies, small molecule inhibitors, AAVs, and more. It will also include discussions on regulatory and approval pathways, case studies of novel technologies to optimize the translatability of ALS models and biomarkers, and examples of clinical trial designs incorporating digital monitoring technologies, surrogate endpoints, and combination regimens.

AcuraStem is dedicated to advancing ALS research through its best-in-class disease modeling platform, iNeuroRx®, which enables the discovery of innovative, effective, and broadly acting treatments.The company is committed to developing innovative therapies for neurodegenerative diseases and translating groundbreaking research into clinical applications.

AcuraStem’s participation in the 3rd Annual ALS Drug Development Summit emphasizes its commitment to the ALS community and its mission to bring effective therapies from the lab to patients. The company invites the broader community to continue supporting ALS research and advocacy efforts. Contributions to ALS research can make a meaningful difference in the lives of those affected by ALS and their families.

For more information about AcuraStem’s trail-blazing work, please visit




About AcuraStem

AcuraStem is a patient-based biotechnology company pioneering treatments for neurodegenerative diseases including sporadic ALS and FTD. AcuraStem’s best-in-class disease modeling platform, iNeuroRx®, enables the discovery of innovative, effective, and broadly acting treatments. The team’s strong expertise in ASO technology provides for the rapid advancement of treatments to the clinic. AcuraStem’s research is funded in part by support from the Alzheimer’s Drug Discovery Foundation, Harrington Discovery Institute, Alzheimer’s Association, Rainwater Charitable FoundationMuscular Dystrophy AssociationDepartment of Defense and the National Institute of Neurological Disorders and Stroke.


Kissy Black
Director of Communications, AcuraStem